These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35107074)

  • 1. Scarring alopecia developing after mogamulizumab-associated rash.
    Raval NS; Snowden CK; De Monnin KS; Yokoyama CC; Choi J; Mehta-Shah N; Rosman IS; Pavlisin J; Musiek AC
    Eur J Dermatol; 2021 Dec; 31(6):841-843. PubMed ID: 35107074
    [No Abstract]   [Full Text] [Related]  

  • 2. Mogamulizumab-associated rash - Case series and review of the literature.
    Hansen I; Abeck F; Menz A; Schneider SW; Booken N
    J Dtsch Dermatol Ges; 2024 Aug; 22(8):1079-1086. PubMed ID: 38924340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.
    Ricci C; Pileri A; Agostinelli C; Ambrosi F; Zinzani PL; Sabattini E
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1263-1265. PubMed ID: 30277017
    [No Abstract]   [Full Text] [Related]  

  • 4. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose?
    Oskan F; Belka C; Manapov F
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome.
    Jawed SI; Busam K; Wang X; Horwitz S; Querfeld C
    JAMA Dermatol; 2014 Sep; 150(9):1021-3. PubMed ID: 25029560
    [No Abstract]   [Full Text] [Related]  

  • 6. Histopathologic Characterization of Mogamulizumab-associated Rash.
    Wang JY; Hirotsu KE; Neal TM; Raghavan SS; Kwong BY; Khodadoust MS; Brown RA; Novoa RA; Kim YH; Rieger KE
    Am J Surg Pathol; 2020 Dec; 44(12):1666-1676. PubMed ID: 32976123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistent neutrophilic scarring alopecia triggered by anti-TNF blockade for Crohn's disease.
    Amschler K; Mc Broekaert S; Mohr J; Schön MP; Mößner R
    Eur J Dermatol; 2018 Jun; 28(3):403-405. PubMed ID: 29976546
    [No Abstract]   [Full Text] [Related]  

  • 8. Scarring alopecia following gold therapy.
    Burrows NP; Grant JW; Crisp AJ; Roberts SO
    Acta Derm Venereol; 1994 Nov; 74(6):486. PubMed ID: 7701895
    [No Abstract]   [Full Text] [Related]  

  • 9. Psoriasiform rash following maculopapular eruption during the continued administration of pembrolizumab.
    Sato M; Yamamoto T
    An Bras Dermatol; 2024; 99(5):786-788. PubMed ID: 38945752
    [No Abstract]   [Full Text] [Related]  

  • 10. Will cetuximab-induced follicular rash get worse with moisturizers containing liquid paraffinum?
    Manganoni AM; Pavoni L; Calzavara-Pinton P
    Jpn J Clin Oncol; 2014 Jun; 44(6):607-8. PubMed ID: 24755543
    [No Abstract]   [Full Text] [Related]  

  • 11. Nimotuzumab: evidence of clinical benefit without rash.
    Allan DG
    Oncologist; 2005 Oct; 10(9):760-1. PubMed ID: 16249358
    [No Abstract]   [Full Text] [Related]  

  • 12. Mogamulizumab-induced vitiligo in patients with Sézary syndrome: three cases.
    Algarni AS; Ram-Wolff C; Bagot M; De Masson A
    Eur J Dermatol; 2021 Apr; 31(2):213-216. PubMed ID: 33814357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
    Shih YH; Chen PC; Chu CY
    J Clin Oncol; 2013 Jul; 31(20):e335-7. PubMed ID: 23715581
    [No Abstract]   [Full Text] [Related]  

  • 14. Scarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib.
    Hepper DM; Wu P; Anadkat MJ
    J Am Acad Dermatol; 2011 May; 64(5):996-8. PubMed ID: 21496710
    [No Abstract]   [Full Text] [Related]  

  • 15. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
    Blackmon AL; Pinter-Brown L
    Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
    Lewis DJ; Rook AH
    Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab-induced crusted pustular eruption with patchy alopecia.
    Fischer R; Blackmon J; Rajpara A
    Dermatol Online J; 2014 Oct; 20(10):. PubMed ID: 25526010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
    Donovan JC; Ghazarian DM; Shaw JC
    Arch Dermatol; 2008 Nov; 144(11):1524-5. PubMed ID: 19015435
    [No Abstract]   [Full Text] [Related]  

  • 19. Mogamulizumab-induced toxicoderma-like eruptions and autoimmune hepatitis successfully treated with azathioprine in adult T-cell leukaemia/lymphoma.
    Nishizawa A; Ishikawa T; Hirose M; Satoh H; Nishii S; Tomita K; Hokari R; Satoh T
    Eur J Dermatol; 2017 Dec; 27(6):651-652. PubMed ID: 28739547
    [No Abstract]   [Full Text] [Related]  

  • 20. [Mogamulizumab-associated rash: cutaneous T-cell lymphoma in complete remission].
    Leonhardt A; Maurer M; Flaig MJ
    Dermatologie (Heidelb); 2024 Oct; 75(Suppl 1):5-8. PubMed ID: 39278871
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.